Mutation pattern and genotype-phenotype correlations of SETD2 in neurodevelopmental disorders.

Eur J Med Genet

Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Animal Models for Human Diseases, Changsha, China. Electronic address:

Published: May 2021

SETD2 encodes an important protein for epigenetic modification of histones which plays an essential role in early development. Variants in SETD2 have been reported in neurodevelopmental disorders including autism spectrum disorder (ASD). However, most de novo SETD2 variants were reported in different large-cohort sequencing studies, mutation pattern and comprehensive genotype-phenotype correlations for SETD2 are still lacking. We have applied target sequencing to identify rare, clinical-relevant SETD2 variants and detected two novel de novo SETD2 variants, including a de novo splicing variant (NM_014159: c.4715+1G>A) and a de novo missense variant (c.3185C>T: p.P1062L) in two individuals with a diagnosis of ASD. To analyze the correlations between SETD2 mutations and corresponding phenotypes, we systematically review the reported individuals with de novo SETD2 variants, classify the pathogenicity, and analyze the detailed phenotypes. We subsequently manually curate 17 SETD2 de novo variants in 17 individuals from published literature. Individuals with de novo SETD2 variants present common phenotypes including speech and motor delay, intellectual disability, macrocephaly, ASD, overgrowth and recurrent otitis media. Our study reveals new SETD2 mutations and provided a relatively homozygous phenotype spectrum of SETD2-related neurodevelopmental disorders which will be beneficial for disease classification and diagnosis in clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2021.104200DOI Listing

Publication Analysis

Top Keywords

setd2 variants
20
novo setd2
16
setd2
12
correlations setd2
12
neurodevelopmental disorders
12
mutation pattern
8
genotype-phenotype correlations
8
setd2 mutations
8
individuals novo
8
variants
7

Similar Publications

Introduction: Clinical presentation and genetic profile of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are highly variable, hampering their management. Sequencing of circulating tumor DNA from liquid biopsy (LB) has been proposed as a less invasive alternative to solid biopsy (SB). Our aim was to compare the mutational profile (MP) provided by LB with that deriving from SB in GEP-NETs.

View Article and Find Full Text PDF
Article Synopsis
  • * The study involved whole-exome sequencing of 48 tumor samples, identifying key genetic mutations and patterns related to neuroblastoma through bioinformatics analysis, including the discovery of a novel mutation.
  • * A total of 11 potentially actionable mutations and several cancer driver genes were identified, which could serve as therapeutic targets and offer insights into the disease's molecular mechanisms.
View Article and Find Full Text PDF

Context-Dependent and Locus-Specific Role of H3K36 Methylation in Transcriptional Regulation.

J Mol Biol

January 2025

Department of Life Sciences and Multitasking Macrophage Research Center, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address:

H3K36 methylation is a critical histone modification involved in transcription regulation. It involves the mono (H3K36me1), di (H3K36me2), and/or tri-methylation (H3K36me3) of lysine 36 on histone H3 by methyltransferases. In yeast, Set2 catalyzes all three methylation states.

View Article and Find Full Text PDF

Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome.

Neurooncol Adv

July 2024

Molecular Predictors and New Targets in Oncology, INSERM U981, Team "Genomics and Oncogenesis of pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Article Synopsis
  • Constitutional mismatch repair deficiency (CMMRD) leads to a significant cancer risk, primarily resulting in high-grade gliomas in children due to mutations in mismatch repair genes.
  • Analysis of clinical and genetic data from 12 affected children revealed that 50% of their glioma samples expressed PDL1 and exhibited an ultra-hypermutated phenotype, with numerous mutations and specific driver mutations identified.
  • The research indicates that CMMRD gliomas have distinct oncogenic properties, differing from typical glioblastomas, suggesting potential for targeted therapies, particularly those targeting MAPK pathways and PD1 inhibitors.
View Article and Find Full Text PDF

Target repositioning using multi-layer networks and machine learning: The case of prostate cancer.

Comput Struct Biotechnol J

December 2024

Molecular Medicine Department, CHU de Québec Research Center, Université Laval, Québec, QC, Canada.

The discovery of novel therapeutic targets, defined as proteins which drugs can interact with to induce therapeutic benefits, typically represent the first and most important step of drug discovery. One solution for target discovery is target repositioning, a strategy which relies on the repurposing of known targets for new diseases, leading to new treatments, less side effects and potential drug synergies. Biological networks have emerged as powerful tools for integrating heterogeneous data and facilitating the prediction of biological or therapeutic properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!